Tribune: Abbott didn't want all of Wyeth

Abbott Laboratories, rumored to be interested in the takeover of drug giant Wyeth, may only have been interested in pieces of the New Jersey-based maker of vaccines and drugs, sources and industry analysts told the Chicago Tribune. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.